Key facts
- This page summarizes Marcus Schulz's Form 4 filing for BIOLIFE SOLUTIONS INC (BLFS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Jan 2023, 18:01.
Marcus Schulz - 03 Jan 2023 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)
- Reporting relationship
- Chief Revenue Officer
- Issuer ticker
- BLFS
- Reported as of
- 03 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jan 2023, 18:01:49 UTC
- Prior SEC filing
- 14 Nov 2022
- Next SEC filing
- 12 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marcus Schulz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Marcus Schulz filed Form 4 for BIOLIFE SOLUTIONS INC (BLFS) on 10 Jan 2023.
Change
- Previous filing in this sequence was filed on 14 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BLFS
transaction
Common Stock
Award
- Transaction value
- Shares
- +12,733
- Change %
- +36%
- Price
- Shares after
- 48,233
- Date
- 03 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BLFS
transaction
Derivative
Restricted Stock Award
Award
- Transaction value
- $0
- Shares
- +12,733
- Change %
- Price
- $0.000000
- Shares after
- 12,733
- Date
- 03 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,733
- Exercise price
- $0.000000
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation.
Footnote F2
The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.